Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201142 | 0.92 | HPGD (0.49) | HPGDCHRM4ALOX15MAPTMEN1 | |
| SCHEMBL20201143 | 0.92 | HPGD (0.43) | HPGDL3MBTL1CHRM4ALOX15MAPT | |
| SCHEMBL20201146 | 0.90 | HPGD (0.42) | HPGDL3MBTL1CHRM4ALOX15CRHR1 | |
| SCHEMBL18216473 | 0.90 | HPGD (0.43) | HPGDL3MBTL1CHRM4ALOX15MAPT | |
| SCHEMBL20201145 | 0.89 | HPGD (0.41) | HPGDL3MBTL1CHRM4MAPTMEN1 | |
| SCHEMBL20205281 | 0.89 | L3MBTL1 (0.41) | HPGDL3MBTL1CHRM4ALOX15MAPT | |
| SCHEMBL20205096 | 0.88 | HPGD (0.40) | HPGDL3MBTL1CHRM4ALOX15MAPT | |
| SCHEMBL20205023 | 0.87 | HPGD (0.40) | HPGDL3MBTL1CHRM4MAPTMEN1 | |
| SCHEMBL18216464 | 0.87 | KMT2A (0.47) | HPGDCHRM4ALOX15MAPTMEN1 | |
| SCHEMBL18216276 | 0.86 | MAPT (0.42) | HPGDL3MBTL1CHRM4MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | HPGD 565/4885L3MBTL1 2341/4885CHRM4 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.